α-PiHP
α-pyrrolidinoisohexanophenone
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
α-PiHP (α-pyrrolidinoisohexanophenone) is a synthetic stimulant of the substituted cathinone class. It is a positional isomer of α-PHP, sharing the same molecular scaffold but with a branched rather than straight side chain.[1] It blocks dopamine and norepinephrine reuptake, prolonging their activity in the brain's reward and arousal circuits.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
α-PVP, α-PHP, MDPV +3 moreα-PVP, α-PHP, MDPV, other pyrovalerone cathinones, cocaine (partial), amphetamines (partial) show less
α-PiHP was designed in 2016 as a structural replacement for α-PVP and α-PHP as those compounds were scheduled.[3] It spread rapidly across European markets, reaching the top five synthetic cathinones seized by weight by 2022.[4] The WHO recommended international control in late 2022, and it entered Schedule II of the 1971 Convention in March 2023.[5][1]
Subjective effects include psychomotor stimulation, euphoria, wakefulness, focused energy, and sharp urges to redose. The experience is narrowly stimulant — intense dopamine-driven activation without the warmth or social ease of compounds that also activate serotonin.[6] Anxiety, paranoia, and rapid heart rate are characteristic unsought effects.[1]
α-PiHP carries high psychological dependence liability and dose-dependent cardiovascular toxicity with no established lethal threshold.[7][8] Blood pressure elevation outlasts cocaine at comparable intranasal doses, and fatal cardiac arrest is documented; polydrug use is present in nearly all recorded fatalities.[9][10] Understanding rests primarily on forensic case series and a single naturalistic pharmacokinetic study; no clinical trials have been conducted.
History[edit]
Discovery
α-PiHP was engineered as a structural variant of α-PHP — itself a successor to α-PVP and MDPV — designed to exploit regulatory gaps as predecessor compounds were sequentially scheduled.[3] It was first identified in seized material in China in 2016, with Hungary and Slovenia reporting independent detections the same year.[11]
Market trajectory
α-PiHP followed the standard pattern of synthetic cathinone markets: each new compound fills the niche left by its newly scheduled predecessor.[3] By 2022 it ranked among the top five synthetic cathinones seized by weight across Europe.[4] In the United Kingdom it has been identified as a component of "monkey dust" — mixed pyrovalerone street preparations linked to severe intoxication presentations in North Staffordshire.[12]
International scheduling
The WHO Expert Committee evaluated α-PiHP in October 2022, concluding it inhibits dopamine and norepinephrine uptake more potently than cocaine and methamphetamine.[5] It entered Schedule II of the 1971 Convention in March 2023, with the EU adopting controls the same month and the United States adding a specific Schedule I listing in December 2023.[1][13]
The name α-PiHP (also written α-PHiP) derives from systematic cathinone nomenclature: "pyrrolidino" for the nitrogen ring, "iso" for the branched chain, and "hexanophenone" for the six-carbon ketone backbone. The "iso" prefix is the compound's entire identity — it marks the single methyl branch that distinguishes it from its linear-chain isomer α-PHP. Within research chemical communities, α-PiHP is sometimes discussed as a "legal α-PHP," reflecting its origin as a regulatory workaround rather than a pharmacological innovation.
Chemistry[edit]
Structural class
α-PiHP belongs to the pyrovalerone subclass of substituted cathinones — a family of synthetic stimulants built on a phenethylamine backbone with a ketone group and a nitrogen incorporated into a pyrrolidine ring.
It is a positional isomer of α-PHP, with the same molecular formula (C₁₆H₂₃NO, 245.36 g/mol) but a branched isobutyl side chain where α-PHP carries a straight chain.[1] That single structural difference produces measurable pharmacokinetic changes while leaving the core mechanism intact.[4]
Molecular properties
The molecule consists of a phenyl ring attached to an α-aminoketone core, with the nitrogen in a five-membered pyrrolidine ring and the aliphatic chain extending as a branched isobutyl group.[14] In vitro studies show moderate metabolic resistance — approximately 65% of the parent compound remained intact after five hours of incubation with human liver enzymes.[15]
Pharmacology[edit]
Mechanism of action
α-PiHP blocks the dopamine and norepinephrine transporters, preventing these neurotransmitters from clearing after release.[2] It is a pure reuptake inhibitor — it amplifies signals that are already occurring rather than forcing a flood of stored neurotransmitters out, as amphetamines do. Serotonin transporter activity is negligible, giving α-PiHP high selectivity for dopamine and correspondingly high abuse liability.[7][16]
Pharmacokinetics
The first human pharmacokinetic data came from a 2025 observational study in which 17 adults self-administered α-PiHP intranasally at 15–25 mg, with cocaine as a within-session comparator.[9] Peak concentration in oral fluid was reached within approximately 20 minutes; the plasma half-life was approximately 1.1 hours. Cardiovascular effects — elevated heart rate and blood pressure — were more sustained than those produced by cocaine at the comparator dose.[9]
Metabolism
Ten urinary metabolites have been identified in human users.[11] The major pathways are reduction of the ketone group and hydroxylation of the side chain; the hydroxylation metabolite distinguishes α-PiHP from α-PHP in urine testing.[15] In postmortem tissue, this metabolite is detected alongside the parent compound across all major organs.[17]
Neuroscience[edit]
Where it acts
α-PiHP concentrates its effects in two neural systems. In the mesolimbic pathway — the brain's reward circuit — elevated dopamine drives the intense but narrow reward signal that defines the experience.[7] The absence of serotonin engagement means this reward lacks the prosocial warmth seen with MDMA-like compounds. Elevated norepinephrine in the arousal system drives wakefulness, rapid heart rate, and blood pressure elevation.[9][10]
Why it matters
The reward circuit distinguishes between wanting — the compulsive drive to seek the drug — and liking — the actual pleasure of having it. Selective dopamine reuptake inhibitors amplify wanting more than liking, which is why the compulsive redosing urge persists even after subjective pleasure fades.[6] At high doses or during extended binges, excessive dopamine activation produces paranoia, hallucinations, and delusional thinking.[1][18][16]
Whether α-PiHP damages dopaminergic nerve terminals — as chronic methamphetamine does — is unknown; neurotoxicity is identified as a plausible but unquantified risk for the synthetic cathinone class.[18] The hydroxylated metabolite OH-α-PiHP is consistently detected at concentrations comparable to the parent compound in postmortem tissue,[17] but whether it crosses into the brain and contributes to central effects has not been investigated.
Subjective Effects[edit]
The α-PiHP experience is narrowly stimulant. The activation is intense — focused energy, heightened alertness, and a sharp dopaminergic rush — but it lacks the warmth, social ease, or emotional openness of compounds that also activate serotonin. The high peaks quickly and drops fast, leaving a strong pull toward the next dose.[1]
The closest comparator is α-PVP, which shares the same reuptake-inhibitor mechanism but hits harder per milligram.[4] Against cocaine, α-PiHP produces broadly similar stimulation at recreational intranasal doses but with more sustained cardiovascular effects and a qualitatively colder, less serotonergically modulated character.[9]
Effect Grid
Clear stimulant effects dominate — pronounced cognitive euphoria, marked wakefulness, and appetite suppression. Focus enhancement and motivation enhancement are prominent. Thought acceleration is obvious, and users may experience increased sociability, though without the empathogenic warmth of serotonergic stimulants due to α-PiHP's negligible SERT activity.
Physically, heart rate and blood pressure are noticeably elevated — blood pressure elevation is more sustained than with comparable cocaine doses. Excessive sweating, dry mouth, and mild bruxism may occur. Restlessness becomes apparent. Pupil dilation is likely.
The compulsive redosing urge emerges at this tier and can intensify as peak effects begin to fade. This is the range studied in the De la Rosa 2025 human observational study (15–25 mg insufflated). Sleep will be impossible for several hours.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Shadow people
Wakefulness · Dry mouth · Insomnia · Physical fatigue · Restlessness · Body high · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Sexual arousal enhancement · Trembling · Nausea
Restlessness · Body high · Dehydration sensation · Excessive sweating · Heart rate perception changes · Muscle tension · Bruxism · Sexual arousal enhancement · Trembling · Nausea
Thought acceleration · Cognitive dysphoria · Focus enhancement · Information processing enhancement · Motivation enhancement · Analysis enhancement · Cognitive impairment · Thought disorganization · Thought loops · Confusion
Motivation enhancement · Analysis enhancement · Cognitive impairment · Thought disorganization · Thought loops · Confusion
Irritability · Dysphoria · Emotional lability
Sociability suppression
Timeline
First awareness of stimulation with a subtle mood lift and increased alertness. Physical effects are minimal — slight heart rate increase may be noticed.
Rapidly building euphoria, wakefulness, and physical activation. Focus sharpens and thought acceleration becomes apparent. Heart rate and blood pressure begin rising.
Maximum euphoria and stimulation with pronounced cardiovascular effects. Compulsive redosing urge is strongest during this phase and into early offset. Blood pressure elevation exceeds that of comparable cocaine doses.
Gradual reduction in euphoria with residual stimulation persisting. Anxiety and dysphoria may emerge as dopaminergic reward fades while noradrenergic activation continues. Appetite remains suppressed.
Residual wakefulness and difficulty sleeping with possible mild dysphoria, fatigue, and anhedonia. Physical restlessness may persist.
⚠ Avoid driving during the afterglow period — residual stimulation and fatigue may impair reaction time and judgment.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- rapid
- Tolerance reset
- 5 days
- Physical
- Negligible
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- α-PVP · α-PHP · MDPV
Toxicity
No lethal dose has been established in any species. Postmortem blood concentrations overlap substantially between non-fatal and fatal exposures, making it impossible to define a reliable toxic threshold.[8]safety citation needed
Acute toxicity
α-PiHP intoxication presents as stimulant overdrive: rapid heart rate, elevated blood pressure, elevated body temperature, agitation, and sweating.[9][1] In the only human pharmacokinetic study, blood pressure elevation after intranasal α-PiHP (15–25 mg) was more sustained than after intranasal cocaine (75–90 mg).[9]
Heart and circulation
Cardiovascular failure is the primary lethal mechanism. Documented outcomes include rapid heart rate and elevated blood pressure at recreational doses,[9] cardiac rhythm disturbances,[1] and sudden cardiac arrest — including a fatal case involving co-ingestion with tramadol.[10]
Sudden cardiac death was the predominant cause in a Finnish postmortem series covering synthetic cathinone deaths from 2018–2023.[19]
Dangerous overheating
Life-threatening overheating has been documented following massive oral ingestion (approximately 5 grams), with severe muscle breakdown and acute kidney injury from sustained muscular hyperactivity.[20] The skeletal muscle relaxant dantrolene produced prompt temperature reduction in that case.
Fatal cases
Multiple fatalities are documented, nearly always involving other substances. In a Finnish postmortem series, 82% of decedents were male with a median age of 35; opioids, stimulants, or sedatives were co-detected in 69–92% of cases, and only 1.7% of cathinone deaths had a cathinone as the sole detected substance.[19]
The first confirmed fatality primarily attributed to α-PiHP included comprehensive tissue distribution and detection of the hydroxylated metabolite across all major organs.[17]
Clinical management
No specific antidote exists.[21] Treatment follows standard stimulant overdose protocols: active cooling, intravenous fluids, and benzodiazepines for agitation.[21] Dantrolene may be considered for hyperthermia unresponsive to standard cooling.[20]
Psychological risks
At recreational doses, α-PiHP produces anxiety and paranoia consistent with its dopamine-selective pharmacology.[1][18] At higher doses and during sustained binge use, psychotic features emerge: hallucinations, persecutory delusions, and severe agitation.[1][22] Forensic cases frequently document aggressive and violent behavior.[16]
Extreme agitation with elevated body temperature, unusual physical strength, and loss of pain sensitivity — documented for the pyrovalerone cathinone class — carries high mortality risk.[23] Class-level evidence suggests post-acute anxiety, depression, and anhedonia following chronic use.[6][18]
Tolerance and dependence
No α-PiHP-specific tolerance or dependence studies have been published.inferred The WHO assessed it as having high abuse potential based on animal self-administration models and a pharmacological profile comparable to cocaine and methamphetamine.[5]
Tolerance builds rapidly during binge use, requiring escalating doses to maintain euphoric effects.[6] The short-lived high drives compulsive redosing.[6][18] Withdrawal is primarily psychological — cravings, anhedonia, fatigue, and low mood — rather than the physiological withdrawal seen with opioids or benzodiazepines.[6]
Drug interactions
No controlled interaction studies exist. The following are based on co-occurrence in fatal or severe cases, or inferred from mechanism.
Opioids
Co-administration with opioids appears in the majority of α-PiHP-related fatalities.[19] The stimulant component masks progressive respiratory depression from the opioid, while both compounds add cardiovascular stress.safety citation needed
Tramadol
A fatal case documented cardiac arrest with α-PiHP and tramadol at toxic concentrations.[10] Tramadol adds monoamine reuptake inhibitor, lowers seizure threshold, and may prolong cardiac rhythm intervals.
Benzodiazepines
Frequently co-detected in intoxication cases.[16][19] Benzodiazepines may suppress agitation without addressing cardiovascular toxicity, creating a false sense of stability.
MAO inhibitors
No published case reports were identified. Blocking monoamine breakdown while also blocking reuptake produces dangerous accumulation of dopamine and norepinephrine, risking a severe blood pressure crisis.safety citation needed
Other stimulants
Multi-cathinone use is documented in forensic series.[16][8] Cardiovascular load is additive to synergistic.
Alcohol
Co-detected in death series.[19] Adds impaired judgment and worsened temperature regulation.
Pregabalin
Co-detected in German forensic cases.[16] May add central nervous system depression and worsen the post-acute low.
Contraindications
No substance-specific contraindication studies exist.inferred
Heart conditions: α-PiHP produces dose-dependent rapid heart rate and sustained blood pressure elevation.[9] Pre-existing coronary artery disease, rhythm disturbances, heart muscle disease, or uncontrolled blood pressure are absolute contraindications. Sudden cardiac arrest has been documented.[10][19]
Psychiatric disorders: Psychotic spectrum disorders, bipolar disorder, and severe anxiety disorders are absolute contraindications. α-PiHP precipitates hallucinations and delusions at high doses,[1] with specific risk for psychotic decompensation in predisposed individuals.
Seizure disorders: Stimulants lower seizure threshold. No α-PiHP-specific seizure cases are documented, but the class-level risk is established.safety citation needed
MAO inhibitor therapy: Concurrent use with any monoamine oxidase inhibitor is an absolute contraindication due to risk of severe blood pressure crisis.safety citation needed
Kidney impairment: α-PiHP-induced muscle breakdown and acute kidney injury are documented.[20] Pre-existing kidney disease increases vulnerability.
Pregnancy and lactation: No reproductive toxicity data exist. Stimulants pose risks to fetal cardiovascular development and placental blood flow.safety citation needed
Harm Reduction[edit]
Forms & Identification
α-PiHP is nearly indistinguishable from α-PHP by appearance — both circulate as white to off-white crystalline powders. Specialized mass spectrometric methods were developed specifically because standard testing cannot reliably differentiate the two isomers.[15] Reagent testing can confirm the cathinone class but cannot identify which pyrovalerone structural analog is present.
Street preparations sold as α-PiHP may contain other active cathinones. "Monkey dust" blends in the United Kingdom document this pattern.[12] Any dosing decision must account for that uncertainty.
Guidelines
- Test all material with reagent kits to confirm cathinone class; understand that specific identity cannot be verified without laboratory analysis
- Start with the lowest reported active dose via the intended route; do not redose within 90 minutes regardless of perceived lack of effect
- Weigh doses with a milligram-precision scale — never estimate by eye
- Avoid vaporization and intranasal routes if unable to resist compulsive redosing; oral administration's slower onset reduces but does not eliminate this risk
- Set a firm time limit and dose cap before the session; communicate both to a sitter or trusted contact
- Remove additional supply from immediate access once the session begins
- Stay hydrated but do not over-hydrate; eat a light meal beforehand
- Monitor heart rate if possible; rest and seek help if sustained rapid heartbeat exceeds baseline by 50% or more
Set & Setting
The anxiety α-PiHP produces is highly sensitive to environment. The same pharmacological arousal that reads as focused energy in a calm, familiar setting can become paranoia and agitation in an unfamiliar or overstimulating one. A quiet, controlled environment with trusted company reduces the risk of anxiety escalating to panic.
Solitary use increases vulnerability to compulsive redosing cycles and delays recognition of medical emergencies.
Aftercare & integration. The comedown from α-PiHP is characterized by fatigue, low mood, irritability, and difficulty sleeping despite physical exhaustion. These effects reflect temporary dopamine depletion and typically resolve within 24–72 hours.
Prioritize sleep — use a dark, quiet room and avoid screens. Eat nutrient-dense food even if appetite is suppressed. Stay hydrated. Avoid caffeine and other stimulants during recovery. Light physical exercise can help restore baseline mood, but the cardiovascular system needs rest after sustained stimulant-driven elevation.
If anxiety, paranoia, or low mood persist beyond 72 hours, or if psychotic symptoms occurred during use, consult a healthcare provider. Repeated binge-crash cycles escalate rapidly with pyrovalerone cathinones.
Recovery & Support
α-PiHP carries high psychological dependence liability. The compulsive redosing pattern characteristic of pyrovalerone cathinones means problematic use can develop rapidly, often within weeks of regular use.
Stimulant-specific recovery resources include SMART Recovery (evidence-based self-management), Crystal Meth Anonymous (applicable to cathinone stimulant patterns), and local addiction services accessible through national helplines. No pharmacological treatment specific to cathinone dependence exists, but behavioral therapies — particularly contingency management and cognitive behavioral therapy — have demonstrated effectiveness for stimulant use disorders.
Contact a healthcare provider, counselor, or peer support group as a concrete first step.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain or pressure, seizure, loss of consciousness, body temperature hot to the touch through clothing, severe confusion, or extreme agitation that cannot be talked down — any of these signals a medical emergency, not a difficult experience.
Immediate steps:
- 1. Call emergency services immediately
- 2. Move the person to a cool environment and remove excess clothing
- 3. If unconscious but breathing, place in the recovery position (on their side, airway clear)
- 4. Do not restrain unless there is immediate danger of self-harm or harm to others
- 5. Do not induce vomiting
- 6. Apply cool (not ice-cold) water to the neck, armpits, and groin if overheating is suspected
- 7. Stay with the person until help arrives
What to tell the dispatcher: The substance name (α-PiHP, a synthetic cathinone), the amount taken if known, the time of last dose, the route of administration, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
No reversal agent exists for α-PiHP or any synthetic cathinone.
Legal Status[edit]
α-PiHP is internationally controlled under Schedule II of the 1971 United Nations Convention on Psychotropic Substances, effective March 2023.[5][1] Most major jurisdictions have implemented specific or generic controls.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United Nations | Schedule II (1971 Convention) | International control effective March 2023[1] |
| United States | Schedule I (Controlled Substances Act) | Specific listing established 13 December 2023, DEA code 7551; previously controlled implicitly as positional isomer of α-PHP[13] |
| European Union | Controlled (Council Decision (EU) 2023/567) | Union-wide control measures effective 9 March 2023; detected in 18 Member States, controlled in at least 7 before harmonization[1] |
| United Kingdom | Class B (Misuse of Drugs Act 1971) | Controlled under the generic cathinone structural definition since 2010; 125 seizure detections recorded 2020–2023[12] |
| Australia | Controlled substance | Listed by the Office of Drug Control; confirmed in force as of 2024citation needed |
| Canada | Controlled (analog provision) | Controlled Drugs and Substances Act; case-by-case analog assessmentcitation needed |
| China | Controlled | First detected and scheduled in 2016[1] |
Legal status changes frequently and varies by jurisdiction. This information is for harm reduction purposes only and is not legal advice.
references
- [1]
- [2] ^abKolaczynska KE, Thomann J, Hoener MC, Liechti ME (2021) The Pharmacological Profile of Second Generation Pyrovalerone Cathinones and Related Cathinone Derivative. — International journal of molecular sciences doi:10.3390/ijms22158277
- [3] ^abcKuropka P, Zawadzki M, Szpot P (2022) A review of synthetic cathinones emerging in recent years (2019–2022). — Forensic Toxicology doi:10.1007/s11419-022-00639-5
- [4] ^abcdBaarset AM, Steinsland S, Nerem E, Andersen JM, Baumann MH, Bogen IL (2025) Pharmacological effects and pharmacokinetics of the novel synthetic cathinone α-pyrrolidinoisohexanophenone (α-PiHP) compared with α-pyrrolidinovalerophenone (α-PVP) in mice — Neurotoxicology doi:10.1016/j.neuro.2025.05.005
- [5]
- [6]